DUBLIN--(BUSINESS WIRE)--The "Cystic Fibrosis - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Cystic Fibrosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 2, 38, 21, 2, 66, 35 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 1, 10, 9 and 1 molecules, respectively.
Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cystic Fibrosis (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Cystic Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cystic Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cystic Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cystic Fibrosis (Respiratory)
Key Topics Covered:
- Introduction
- Cystic Fibrosis - Overview
- Cystic Fibrosis - Therapeutics Development
- Cystic Fibrosis - Therapeutics Assessment
- Cystic Fibrosis - Companies Involved in Therapeutics Development
- Cystic Fibrosis - Drug Profiles
- Cystic Fibrosis - Dormant Projects
- Cystic Fibrosis - Discontinued Products
- Cystic Fibrosis - Product Development Milestones
- Appendix
Companies Mentioned
- 4D Molecular Therapeutics Inc
- AbbVie Inc
- Abeona Therapeutics Inc
- Affinia Therapeutics
- Agile Sciences Inc
- AGILeBiotics BV
- Airbase Breathing Co LLC
- Airway Therapeutics LLC
- Alaxia SAS
- AlgiPharma AS
- Altavant Sciences Inc
- Amgen Inc
- Antabio SAS
- Arch Biopartners Inc
- Arcturus Therapeutics Ltd
- Armata Pharmaceuticals
- Arrevus Inc
- Arrowhead Pharmaceuticals Inc
- AstraZeneca Plc
- Atlantic Healthcare Plc
- Avidin Biotechnology Ltd
- BioAegis Therapeutics Inc
- Biofilm Pharma
- Biolytx Pharmaceuticals Corp
- Boehringer Ingelheim International GmbH
- Boston Pharmaceuticals Inc
- Breathe Easy Therapeutics Ltd
- BridgeBio Pharma Inc
- Calista Therapeutics Inc
- Calithera Biosciences Inc
- Catabasis Pharmaceuticals Inc
- Celtaxsys Inc
- Chiesi Farmaceutici SpA
- Chrysalis Pharma SAS
- Cilian AG
- ContraFect Corp
- Copernicus Therapeutics Inc
- Corbus Pharmaceuticals Inc
- CRISPR Therapeutics AG
- CrowdOut Therapeutics
- CSA Biotechnologies LLC
- Cyclacel Pharmaceuticals Inc
- Cyclenium Pharma Inc
- Daiichi Sankyo Co Ltd
- Destiny Pharma Plc
- DiscoveryBiomed Inc
- Editas Medicine Inc
- Eloxx Pharmaceuticals Inc
- EmphyCorp Inc
- EnBiotix Inc
- enGene Inc
- Enterprise Therapeutics Ltd
- Entrinsic Bioscience Inc
- Enzyvant Sciences Ltd
- Errant Gene Therapeutics LLC
- Evaxion Biotech ApS
- Evotec SE
- Exotect LLC
- F. Hoffmann-La Roche Ltd
- Feldan Therapeutics Inc
- Galapagos NV
- Galenus Therapeutics Inc
- Generation Bio Co
- Genzyme Corp
- Helperby Therapeutics Group Ltd
- Horizon Therapeutics Plc
- Icagen Inc
- Idorsia Pharmaceutical Ltd
- Immun System IMS AB
- Insmed Inc
- Invion Ltd
- Ionis Pharmaceuticals Inc
- Kamada Ltd
- Kither Biotech Srl
- Krystal Biotech Inc
- Lakewood-Amedex Inc
- Lamellar Biomedical Ltd
- Laurel Therapeutics
- Laurent Pharmaceuticals Inc
- MannKind Corp
- Mariposa Health Ltd
- Microbion Corp
- Moderna Inc
- Mucokinetica Ltd
- Nanogenics Ltd
- Neupharma Srl
- New Amsterdam Sciences Inc
- Novabiotics Ltd
- Novoteris LLC
- Omnispirant Ltd
- Orphomed Inc
- OrPro Therapeutics Inc
- Oryn Therapeutics
- Paranta Biosciences Ltd
- Parion Sciences Inc
- Pharmaero ApS
- Pharmaxis Ltd
- PhaseBio Pharmaceuticals Inc
- Polyphor Ltd
- Progenra Inc
- ProQR Therapeutics NV
- Protalix BioTherapeutics Inc
- Proteostasis Therapeutics Inc
- Pulmatrix Inc
- Rare Partners Srl
- Recode Therapeutics Inc
- Renovion Inc
- Riptide Bioscience Inc
- Santhera Pharmaceuticals Holding AG
- SciBac Inc
- Sequoia Sciences Inc
- Silurian Pharmaceuticals Inc
- SolAeroMed Inc
- Specific Biologics Inc
- Spirovant Sciences Inc
- Spyryx Biosciences Inc
- Synedgen Inc
- Synovo GmbH
- Synspira LLC
- Takeda Pharmaceutical Co Ltd
- Tavanta Therapeutics Inc
- TGV-Inhalonix Inc
- Therapeutic Systems Research Laboratories Inc
- Translate Bio Inc
- Vast Therapeutics Inc
- Vectura Group Plc
- Vera Therapeutics Inc
- Verona Pharma Plc
- Vertex Pharmaceuticals Inc
- Vironika LLC
- Zambon Co SpA
- Zata Pharmaceuticals Inc
- Zikani Therapeutics Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/yauvo9
